| Name | N-Despropyl-macitentan |
|---|---|
| Synonyms |
Macitentan N-Despropyl Impurity
N-(5-(4-Bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)sulfamide , Aprocitentan Aprocitentan, 10 mM in DMSO N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]aminosulfonamide N-(5-(4-Bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)sulfamide Dropylmethacetin 5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(sulfamoyl)pyrimidin-4-amine Sulfamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl] N - [5- (4-bromophenyl) -6- [2- [(5-bromo-2-pyrimidinyl) oxy] ethoxy] -4-pyrimidinyl] aminosulfonamide Macitentan Impurity 07 N-Despropyl Macitentan D4-N-Despropyl Macitentan Despropyl Macitentan Despropyl Macitentan (COLD SHIPMENT REQUIRED) Aprocitentan 5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]-ethoxy]-4-pyrimidinyl]sulfamide APROCITENTAN; ACT-132577; ACT 132577; ACT132577; DESPROPYL MACITENTAN Macitentan ACT-132577 N-[5-(4-bromophenyl)-6-[2-(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl 5-(4-BROMOPHENYL)-4-[2-(5-BROMOPYRIMIDIN-2-YL)OXYETHOXY]-6-(SULFAMOYLAMINO)PYRIMIDINE Macitentan ACT-132577-D4 N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]sulfamide |
| Description | ACT-132577 is the major and pharmacologically active metabolite of macitentan, which is dual ETA/ETB antagonist designed for tissue targeting. |
|---|---|
| Related Catalog | |
| In Vitro | ACT-132577 achieves full inhibition of intracellular calcium increase induced by ET-1 on nonrecombinant cells (primary human pulmonary smooth muscle cells and rat aortic smooth muscle cell line A10 and mouse fibroblast cell line 3T3)[1]. |
| In Vivo | ACT-132577 has a volume of distribution greater than the plasma volume and a longer half-life than its parent compound in the rat[1]. In rat plasma, the mean recovery of ACT-132577 ranges from 82.6% to 90.6%, matrix effect of ACT-132577 in rat plasma ranges from 101.4% to 115.2%[2]. |
| Kinase Assay | The competition binding assay is performed in 200 μL of 50 mM Tris/HCl buffer, pH 7.4, including 25 mM MnCl2, 1 mM EDTA, 0.5% (w/v) bovine serum albumin (fraction V), and 50 μg/mL 4-(2-aminoethyl)benzenesulfonyl fluoride in polypropylene microtiter plates. Membranes containing 0.5 μg of protein (ETA) or 0.2 μg of protein (ETB) are incubated for 2 h at room temperature with 16 pM 125I-ET-1 (8000 cpm) and increasing concentrations of unlabeled test compounds. Maximal and minimal binding is determined in samples without and with 100 nM unlabeled ET-1, respectively. After 2 h of incubation, the membranes are filtered onto filter plates containing GF/C filters. To each well, 50 μL of scintillation cocktail is added, and the filter plates counted in a microplate counter. Test compounds are dissolved, diluted, and added to the assay in dimethyl sulfoxide. The final concentration of dimethyl sulfoxide in the assay is 2.5%, which is found not to interfere with the binding. The IC50 value is calculated as the concentration of antagonist inhibiting 50% of the specific binding of ET-1. |
| References |
| Molecular Formula | C16H14Br2N6O4S |
|---|---|
| Molecular Weight | 546.19300 |
| Exact Mass | 543.91600 |
| PSA | 150.59000 |
| LogP | 4.38590 |